BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Scott EN, Gocher AM, Workman CJ, Vignali DAA. Regulatory T Cells: Barriers of Immune Infiltration Into the Tumor Microenvironment. Front Immunol 2021;12:702726. [PMID: 34177968 DOI: 10.3389/fimmu.2021.702726] [Cited by in Crossref: 1] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Sankar S. New insights into CAR T-cell therapy for recurrent head and neck squamous cell carcinoma. Oral Oncol 2022;134:106137. [PMID: 36174455 DOI: 10.1016/j.oraloncology.2022.106137] [Reference Citation Analysis]
2 Terrassoux L, Claux H, Bacari S, Meignan S, Furlan A. A Bloody Conspiracy. Blood Vessels and Immune Cells in the Tumor Microenvironment. Cancers 2022;14:4581. [DOI: 10.3390/cancers14194581] [Reference Citation Analysis]
3 Zhou C, Chen Z, Xiao B, Xiang C, Li A, Zhao Z, Li H. Comprehensive analysis of GINS subunits prognostic value and ceRNA network in sarcoma. Front Cell Dev Biol 2022;10:951363. [DOI: 10.3389/fcell.2022.951363] [Reference Citation Analysis]
4 Song J, Lin Z, Liu Q, Huang S, Han L, Fang Y, Zhong P, Dou R, Xiang Z, Zheng J, Zhang X, Wang S, Xiong B. MiR-192-5p/RB1/NF-κBp65 signaling axis promotes IL-10 secretion during gastric cancer EMT to induce Treg cell differentiation in the tumour microenvironment. Clin Transl Med 2022;12:e992. [PMID: 35969010 DOI: 10.1002/ctm2.992] [Reference Citation Analysis]
5 Hassanian H, Asadzadeh Z, Baghbanzadeh A, Derakhshani A, Dufour A, Rostami Khosroshahi N, Najafi S, Brunetti O, Silvestris N, Baradaran B. The expression pattern of Immune checkpoints after chemo/radiotherapy in the tumor microenvironment. Front Immunol 2022;13:938063. [DOI: 10.3389/fimmu.2022.938063] [Reference Citation Analysis]
6 Hua S, Xie Z, Zhang Y, Wu L, Shi F, Wang X, Xia S, Dong S, Jiang J. Identification and validation of an immune-related gene prognostic signature for clear cell renal carcinoma. Front Immunol 2022;13:869297. [DOI: 10.3389/fimmu.2022.869297] [Reference Citation Analysis]
7 Tian X, Ning Q, Yu J, Tang S. T-cell immunoglobulin and ITIM domain in cancer immunotherapy: A focus on tumor-infiltrating regulatory T cells. Molecular Immunology 2022;147:62-70. [DOI: 10.1016/j.molimm.2022.04.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Xie H, Xu J, Xie Z, Xie N, Lu J, Yu L, Li B, Cheng L. Identification and Validation of Prognostic Model for Pancreatic Ductal Adenocarcinoma Based on Necroptosis-Related Genes. Front Genet 2022;13:919638. [DOI: 10.3389/fgene.2022.919638] [Reference Citation Analysis]
9 Konishi D, Umeda Y, Yoshida K, Shigeyasu K, Yano S, Toji T, Takeda S, Yoshida R, Yasui K, Fuji T, Matsumoto K, Kishimoto H, Michiue H, Teraishi F, Kato H, Tazawa H, Yanai H, Yagi T, Goel A, Fujiwara T. Regulatory T cells induce a suppressive immune milieu and promote lymph node metastasis in intrahepatic cholangiocarcinoma. Br J Cancer 2022. [PMID: 35597869 DOI: 10.1038/s41416-022-01838-y] [Reference Citation Analysis]
10 Delfanti G, Dellabona P, Casorati G, Fedeli M. Adoptive Immunotherapy With Engineered iNKT Cells to Target Cancer Cells and the Suppressive Microenvironment. Front Med 2022;9:897750. [DOI: 10.3389/fmed.2022.897750] [Reference Citation Analysis]
11 Li Y, Yu Y, Kramer A, Hon R, Wilson M, Brown J, Yang L. An Ex Vivo 3D Tumor Microenvironment-Mimicry Culture to Study TAM Modulation of Cancer Immunotherapy. Cells 2022;11:1583. [DOI: 10.3390/cells11091583] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Tao B, Liu Y, Liu H, Zhang Z, Guan Y, Wang H, Shi Y, Zhang J. Prognostic Biomarker KIF18A and Its Correlations With Immune Infiltrates and Mitosis in Glioma. Front Genet 2022;13:852049. [DOI: 10.3389/fgene.2022.852049] [Reference Citation Analysis]
13 Noyes D, Bag A, Oseni S, Semidey-Hurtado J, Cen L, Sarnaik AA, Sondak VK, Adeegbe D. Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells. J Immunother Cancer 2022;10:e004605. [PMID: 35618289 DOI: 10.1136/jitc-2022-004605] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 van Luijk IF, Smith SM, Marte Ojeda MC, Oei AL, Kenter GG, Jordanova ES. A Review of the Effects of Cervical Cancer Standard Treatment on Immune Parameters in Peripheral Blood, Tumor Draining Lymph Nodes, and Local Tumor Microenvironment. J Clin Med 2022;11:2277. [PMID: 35566403 DOI: 10.3390/jcm11092277] [Reference Citation Analysis]
15 Hong Y, Robbins Y, Yang X, Mydlarz WK, Sowers A, Mitchell JB, Gulley JL, Schlom J, Gameiro SR, Sievers C, Allen CT. Cure of syngeneic carcinomas with targeted IL-12 through obligate reprogramming of lymphoid and myeloid immunity. JCI Insight 2022;7:e157448. [PMID: 35260537 DOI: 10.1172/jci.insight.157448] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Nakamura T, Kawakami K, Nomura M, Sato Y, Hyodo M, Hatakeyama H, Hayakawa Y, Harashima H. Combined nano cancer immunotherapy based on immune status in a tumor microenvironment. Journal of Controlled Release 2022. [DOI: 10.1016/j.jconrel.2022.03.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Adeshakin AO, Adeshakin FO, Yan D, Wan X. Regulating Histone Deacetylase Signaling Pathways of Myeloid-Derived Suppressor Cells Enhanced T Cell-Based Immunotherapy. Front Immunol 2022;13:781660. [DOI: 10.3389/fimmu.2022.781660] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
18 Leavenworth JW, Shi LZ, Wang X, Wei H. Editorial: Immune Cell Lineage Reprogramming in Cancer. Front Immunol 2022;12:838464. [DOI: 10.3389/fimmu.2021.838464] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Ly D, Li Q, Navab R, Zeltz C, Fang L, Cabanero M, Zhu CQ, Tsao MS, Zhang L. Tumor-Associated Regulatory T Cell Expression of LAIR2 Is Prognostic in Lung Adenocarcinoma. Cancers (Basel) 2021;14:205. [PMID: 35008369 DOI: 10.3390/cancers14010205] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Fowler D, Nattress C, Navarrete AS, Barisa M, Fisher J. Payload Delivery: Engineering Immune Cells to Disrupt the Tumour Microenvironment. Cancers (Basel) 2021;13:6000. [PMID: 34885108 DOI: 10.3390/cancers13236000] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Dixon ML, Luo L, Ghosh S, Grimes JM, Leavenworth JD, Leavenworth JW. Remodeling of the tumor microenvironment via disrupting Blimp1+ effector Treg activity augments response to anti-PD-1 blockade. Mol Cancer 2021;20:150. [PMID: 34798898 DOI: 10.1186/s12943-021-01450-3] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
22 Capitani N, Patrussi L, Baldari CT. Nature vs. Nurture: The Two Opposing Behaviors of Cytotoxic T Lymphocytes in the Tumor Microenvironment. Int J Mol Sci 2021;22:11221. [PMID: 34681881 DOI: 10.3390/ijms222011221] [Reference Citation Analysis]
23 Liu Y, Zhou X, Wang X. Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities. J Hematol Oncol 2021;14:125. [PMID: 34404434 DOI: 10.1186/s13045-021-01134-x] [Cited by in F6Publishing: 14] [Reference Citation Analysis]